Ascendis Regains Obesity Drug Rights, Launches $400M Buyback
ASND sits 44% above its 52-week low of $186.054.
Summary
Ascendis Pharma regained exclusive worldwide rights to its TransCon technology for obesity and metabolic diseases after terminating its collaboration with Novo Nordisk. The company can now develop and commercialize TransCon semaglutide and other candidates in obesity, Type 2 diabetes, and cardiovascular indications. No financial obligations remain between the parties; the original deal had up to $285 million in milestone payments. Separately, the board authorized a $400 million share repurchase, signaling confidence in the pipeline and cash position. This follows positive TransCon CNP data and a litigation settlement with BioMarin, strengthening the company's strategic position.
At the time of this announcement, ASND was trading at $267.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.5B. The 52-week trading range was $186.05 to $282.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.